Medicare Enrolled
Dr. Sujie Tang, M.D.
Hematology & Oncology · Sherman Oaks, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tang
Dr. Sujie Tang is a hematology & oncology specialist in Sherman Oaks, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Tang performed 10,899 Medicare services across 1,054 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tang received a total of $10,598 from 57 pharmaceutical and/or device companies across 463 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 28% volume in CA
$10,598 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,899
Medicare services
Top 28% in CA for hematology & oncology
1,054
Unique beneficiaries
$39
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~606 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 5,581 | $7 | $13 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,095 | $99 | $207 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
780 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
779 | $100 | $232 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
720 | $125 | $323 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
393 | $66 | $135 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
327 | $1 | $1 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
249 | $142 | $301 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
242 | $26 | $57 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
162 | $59 | $125 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
162 | $120 | $257 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
161 | $14 | $30 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
140 | $11 | $22 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
75 | $1 | $1 |
| New patient office visit, complex (60-74 min) | 33 | $175 | $389 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.2% high complexity
64.1% medium
30.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,598
Total received (2018-2024)
Avg $1,514/year across 7 years
Top 31% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
463
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,017 (94.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$581 (5.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,745
2023
$1,325
2022
$1,114
2021
$1,434
2020
$1,171
2019
$2,076
2018
$1,733
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SUN PHARMACEUTICAL INDUSTRIES INC.
$167
AstraZeneca Pharmaceuticals LP
$166
Exelixis Inc.
$136
Amgen Inc.
$134
Astellas Pharma US Inc
$126
Genentech USA, Inc.
$101
Myriad Genetic Laboratories, Inc.
$81
Incyte Corporation
$79
Daiichi Sankyo Inc.
$78
ADC Therapeutics America, Inc.
$67
TAIHO ONCOLOGY, INC.
$61
PFIZER INC.
$60
INTUITIVE SURGICAL, INC.
$56
E.R. Squibb & Sons, L.L.C.
$52
Lilly USA, LLC
$52
Gilead Sciences, Inc.
$50
Celgene Corporation
$47
GlaxoSmithKline, LLC.
$36
Karyopharm Therapeutics Inc.
$33
Amneal Pharmaceuticals LLC
$29
EMD Serono, Inc.
$28
Radius Health, Inc.
$24
Pharmacosmos Therapeutics Inc.
$23
Novartis Pharmaceuticals Corporation
$21
Janssen Biotech, Inc.
$19
ARRAY BIOPHARMA INC
$19
Top 3 companies account for 26.8% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,218
Amgen Inc.
$826
Takeda Pharmaceuticals U.S.A., Inc.
$725
Astellas Pharma US Inc
$704
PFIZER INC.
$689
GlaxoSmithKline, LLC.
$521
Exelixis Inc.
$518
Lilly USA, LLC
$499
Genentech USA, Inc.
$485
Novartis Pharmaceuticals Corporation
$380
Seagen Inc.
$361
GENZYME CORPORATION
$311
AstraZeneca Pharmaceuticals LP
$283
Incyte Corporation
$218
Karyopharm Therapeutics Inc.
$191
Daiichi Sankyo Inc.
$190
Puma Biotechnology, Inc.
$175
SUN PHARMACEUTICAL INDUSTRIES INC.
$167
Seattle Genetics, Inc.
$161
Gilead Sciences, Inc.
$125
Merck Sharp & Dohme Corporation
$120
Teva Pharmaceuticals USA, Inc.
$119
Octapharma USA, Inc.
$108
Janssen Biotech, Inc.
$104
Myriad Genetic Laboratories, Inc.
$101
Boehringer Ingelheim Pharmaceuticals, Inc.
$88
TAIHO ONCOLOGY, INC.
$88
MEDIVATION FIELD SOLUTIONS LLC
$84
INSYS Therapeutics Inc
$81
ADC Therapeutics America, Inc.
$67
MorphoSys, US Inc.
$66
Coherus Biosciences Inc.
$62
INTUITIVE SURGICAL, INC.
$56
Medtronic USA, Inc.
$55
Regeneron Healthcare Solutions, Inc.
$51
Alexion Pharmaceuticals, Inc.
$50
EMD Serono, Inc.
$48
Celgene Corporation
$47
EISAI INC.
$43
Eisai Inc.
$42
ImmunoGen, Inc.
$41
Amneal Pharmaceuticals LLC
$29
Dendreon Pharmaceuticals LLC
$28
Radius Health, Inc.
$24
TerSera Therapeutics LLC
$23
Pharmacosmos Therapeutics Inc.
$23
Clovis Oncology, Inc.
$22
Myovant Sciences Inc.
$22
AbbVie Inc.
$22
Aurobindo Pharma USA, Inc.
$20
ARRAY BIOPHARMA INC
$19
Merck Sharp & Dohme LLC
$18
Shionogi Inc
$18
PUMA BIOTECHNOLOGY, INC.
$17
Mirati Therapeutics, Inc.
$17
EUSA Pharma (US) LLC
$14
TESARO, Inc.
$14
Top 3 companies account for 26.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AVASTIN · Alecensa · Aranesp · Avastin · BAVENCIO · BENDEKA · BLENREP · Bavencio · CABLIVI · CABOMETYX · COSELA · CUTAQUIG · CYRAMZA · Cabometyx · DARZALEX · Da Vinci Surgical System · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EVENITY · Elahere · Enhertu · FASENRA · GILOTRIF · IBRANCE · IMFINZI · INLYTA · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KYPHON Balloon Kyphoplasty · Khapzory · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYRISK · Mulpleta · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Odomzo · PANZYGA · PEMAZYRE · PROMACTA · PROVENGE · Padcev · Perjeta · Quzyttir · REBLOZYL · RYBREVANT · RYDAPT · Rubraca · SARCLISA · SPRYCEL · SUTENT · SYNDROS · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tecentriq · Trodelvy · Tymlos · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · ZEJULA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
334
Per 100K population
3.4
County median income
$87,760
Nearest hospital
SHERMAN OAKS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tang is a mixed practice specialist, with above-average Medicare volume (top 28% in CA), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tang experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Tang performed 5,581 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tang receive payments from pharmaceutical companies?
Yes. Dr. Tang received a total of $10,598 from 57 companies across 463 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tang's costs compare to other hematology & oncology specialists in Sherman Oaks?
Dr. Tang's average Medicare payment per service is $39. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Sherman Oaks
Browse hematology & oncology specialists in Sherman Oaks ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology